GlassScriptPhysician profile
Patricia Mareda
NPI 1497726046
$5,189.00
in general payments reported to CMS, 2019-2025
39 companies · $1,059 in 2025
The $1,059 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,118 · 2022: $985 · 2023: $1,003 · 2024: $1,024 · 2025: $1,059.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,036 · Long Term Medical Supply Or Device Loan: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,036.42 |
| Long Term Medical Supply Or Device Loan | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,073.90 | 2021-2025 | Ozempic, Rybelsus, Sogroya |
| Lilly USA, LLC | $652.99 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $457.51 | 2022-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $307.45 | 2021-2023 | Evenity, Prolia, Repatha |
| Antares Pharma, INC. | $262.44 | 2021-2025 | Xyosted, Nocdurna, Tlando |
| Bayer Healthcare Pharmaceuticals INC. | $249.17 | 2021-2024 | |
| Medtronic, INC. | $212.37 | 2021-2025 | Minimed 780g |
| Abbott Laboratories | $208.43 | 2021-2025 | Freestyle Libre 3, Freestyle Insulinx |
| Cequr Corporation | $188.00 | 2025 | Cequr Simplicity |
| Amneal Pharmaceuticals LLC | $142.68 | 2021-2024 | Unithroid |
| Insulet Corporation | $128.87 | 2025 | Omnipod |
| Horizon Therapeutics Plc | $125.00 | 2022 | |
| Sanofi-Aventis U.S. LLC | $108.32 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.07 | 2021-2024 | Tradjenta, Jardiance |
| Recordati_rare_diseases_inc. | $102.16 | 2021-2024 | Signifor Lar, Isturisa |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Mareda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.